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A B S T R A C T
Pancreatic cancer (PC) remains a highly lethal malignancy due to its unusual chemoresistance and high
aggressiveness. A subpopulation of pancreatic tumor cells, known as cancer stem cells (CSCs), is con-
sidered responsible not only for tumor-maintenance, but also for its widespreadmetastasis and therapeutic
failure. Here we investigated the role of p-21 activated kinase 4 (PAK4) in driving PC stemness proper-
ties. Our data demonstrate that triple-positive (CD24+/CD44+/EpCAM+) subpopulation of pancreatic CSCs
exhibits greater level of PAK4 as compared to triple-negative (CD24−/CD44−/EpCAM−) cells. Moreover, PAK4
silencing in PC cells leads to diminished fraction of CD24, CD44, and EpCAM positive cells. Furthermore,
we show that PAK4-silenced PC cells exhibit decreased sphere-forming ability and increased chemo-
sensitivity to gemcitabine toxicity. PAK4 expression is also associated with enhanced levels of stemness-
associated transcription factors (Oct4/Nanog/Sox2 and KLF4). Furthermore, our data show decreased nuclear
accumulation and transcriptional activity of STAT3 in PAK4-silenced PC cells and restitution of its activ-
ity leads to restoration of stem cell phenotypes. Together, our ﬁndings deliver ﬁrst experimental evidence
for the involvement of PAK4 in PC stemness and support its clinical utility as a novel therapeutic target
in PC.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Pancreatic cancer (PC) is one of the most lethal malignancies and
stands as the fourth leading cause of cancer-related death in the
United States [1]. With continued increases in its incidence andmor-
tality, PC is expected to take over colorectal and breast malignancies
to become second leading cause by the year 2030 or even earlier
[2]. High mortality in PC patients is attributed to late diagnosis and
unusual resistance of the disease to currently available therapeu-
tic modalities [3,4]. Clearly, this dire situation mandates that efforts
should bemade to identify novel biomarkers and therapeutic targets
to enable early detection and eﬃcient treatment based on im-
provedmechanistic understanding of disease progression, metastasis
and therapy-resistance.
A number of studies have demonstrated that a small subpopu-
lation of cells within a tumor, referred as cancer initiating cells/
cancer stem cells (CSCs), is involved in tumor initiation, development,
metastasis as well as in therapy resistance and disease relapse [5–7].
Pancreatic CSCs were isolated, for the ﬁrst time, based on pheno-
typic markers, viz. CD24, CD44 and ESA (also known as EpCAM),
and demonstrated to be highly tumorigenic [8]. Subsequently, several
studies attributed high rate of recurrence and chemoresistance in
PC to pancreatic CSCs [9–13] suggesting that their targeting would
be a logical way to ﬁnd an effective cure. However, underlying mo-
lecular mechanisms and genetic drivers controlling the stemness
phenotypes have remained largely undeﬁned.
The serine/threonine kinase, p21-activated kinase 4 (PAK4), is
essential for embryonic development and is a key regulator of various
cellular processes including cytoskeleton dynamics, cell polarity, etc.
[14–16]. In addition, aberrant expressionof PAK4 is linked to a variety
of human cancers [17–20]. In a sub-set of pancreatic tumor speci-
mens, a chromosomal region 19q13.2-13.3 harboring PAK4 genetic
locus was reported to be ampliﬁed [21]. Recently, we also reported
overexpression of PAK4 in PC and demonstrated its role in prolif-
eration and survival of pancreatic tumor cells [22]. The involvement
of PAK4 in aggressivemalignant phenotypes (EMT, invasion andme-
tastasis) and chemoresistance of various cancers has also been
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reported [23–26]. However, to date there is no direct evidence as-
sociating PAK4 expression with cancer stem cell properties.
In the present study, we investigated the role of PAK4 in main-
tenance of the stemcell-like phenotypes in PC. The data demonstrate
that PAK4 is overexpressed in pancreatic CSCs as compared to non-
CSCs, and its expression is associated with increased sphere-
forming potential and chemoresistance in PC. Furthermore, PAK4
was shown to activate STAT3 signaling to promote sphere forma-
tionaswell as other stem-likephenotypes inPC. Theseﬁndingsdeliver
ﬁrst experimental evidence for involvement of PAK4 in stemness
of PC and further support its clinical utility as a therapeutic target.
Materials and methods
Cell culture
PC cell lines (MiaPaCa and T3M4)weremaintained asmonolayer cultures in RPMI-
1640 (Life Technologies, Carlsbad, CA) with 5% fetal bovine serum (FBS) (Atlanta
Biologicals, Lawrenceville, GA), penicillin (100 units/mL) and streptomycin (100 μg/mL)
(Life Technologies) in a humidiﬁed atmosphere (5% CO2 at 37 °C). The cells express-
ing high level of CD24/CD44/EpCAM surface markers were isolated from MiaPaCa
and T3M4 cells and cultured in Ultra-Low attachment plate/ﬂask (Corning Incor-
porated, Corning, NY) in stem cell culture medium (DMEM:F-12K, 1:1; Life
Technologies) supplemented with B27, basic ﬁbroblast growth factor (bFGF; 20 ng/
mL) and epidermal growth factor (EGF; 20 ng/mL) (Life Technologies), penicillin
(100 units/mL) and streptomycin (100 μg/mL) tomaintain their undifferentiated status.
Cells were routinely monitored for their typical morphology, and intermittently tested
for mycoplasma contamination at our institutional core facility.
Antibodies, siRNAs and plasmids
Anti-PAK4 (rabbit polyclonal), -Sox2, -Nanog, -pSTAT3 (Y705) (rabbit monoclo-
nal) and -STAT3 (mouse monoclonal) antibodies were purchased from Cell Signaling
Technology (Beverly, MA). Anti-KLF4, -Oct4 (mouse monoclonal) were procured from
Abcam (Cambridge, MA). Antibodies targeting Lamin A, α-tubulin (mouse mono-
clonal) and respective anti-mouse or anti-rabbit horseradish peroxidase (HRP)-
conjugated secondary antibodies were procured from Santa Cruz Biotechnology (Santa
Cruz, CA). β-actin (mouse monoclonal) antibody was purchased from Sigma-
Aldrich (St. Louis MO). For isolation of cancer stem-like cells, anti-human
ﬂuorochrome-conjugated antibodies against CD24 (Alexa Fluor-647 conjugated), CD44
(Brilliant violent-421 conjugated) and EpCAM (also known as ESA) (Phycoerythrin/
cy7 conjugated) were procured from BioLegend (San Diego, CA). The construct
EF.STAT3C.Ubc.GFP (Addgene plasmid #24983) was from Linzhao Cheng laborato-
ry and the control vector FUGW (Addgene plasmid #14883) was fromDavid Baltimore
laboratory and both the plasmids were procured from Addgene. All non-target
(ONTARGET plus Non-targeting pool) and target-speciﬁc (ONTARGET plus SMART
pool) siRNAs were from Origene (Rockville, MD).
Isolation of cancer stem cells
MiaPaCa and T3M4 cells were trypsinized, washed with PBS and resuspended
(1 × 106/mL) in PBS containing 2% FBS. Subsequently, cells were incubated with
ﬂuorochrome-conjugated anti-CD24, -CD44 and -EpCAM antibodies (5 μL/106 cells
each) for 15 min on ice. After incubation, cells were washed with PBS, and sub-
jected to sorting of triple positive (CD24+, CD44+ and EpCAM+) and negative (CD24−,
CD44− and EpCAM−) subpopulation of cells using FACS AriaIITM (BD Bioscience).
7-Aminoactinomycin D (7ADD; BD Bioscience) was added to exclude non-viable cells
prior to FACS analysis. Unstained cells were used as control.
ALDEFLUOR assay
ALDEFLUOR assay was performed using ALDEFLOUR™ kit (Stem Cell Technolo-
gies, Vancouver, BC, Canada) according to themanufacturer’s protocol. Brieﬂy, MiaPaCa
and T3M4 cells (2.5 × 105) were incubated in ALDH1 assay buffer containing
ALDH1 substrate (Bodipy Aminoacetaldehyde; BAAA) at 37 °C for 45 min with in-
termittent mixing. After incubation, cells were centrifuged at 250 g for 5 min
and resuspended in 0.5 mL of ALDH1 assay buffer for analysis using FACS
AriaIITM. For control, cells were treated with the ALDH1 enzyme inhibitor
[diethylaminobenzaldehyde (DEAB)]. 7-AAD was added to the cell suspension prior
to FACS analysis for the exclusion of dead cells.
RNA isolation and reverse transcription polymerase chain reaction (RT-PCR)
Total RNA was extracted using TRIzol reagent (Invitrogen) and reverse tran-
scribed using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
Carlsbad, CA) following manufacturer’s instructions as described earlier [27]. Quan-
titative real-time PCR was performed in 96-well plates using cDNA and SYBR Green
Master Mix on an iCycler system (Bio-Rad, Hercules, CA) using speciﬁc sets of primer
pairs (Table S1). The following thermal conditions were used: cycle 1: 95 °C for 10min,
cycle 2 (×40): 95 °C for 10 sec and 58 °C for 45 sec. Threshold cycle (CT) value for
each gene was separately normalized against CT value for GAPDH, and a relative fold-
change in expression with respect to a reference sample was calculated by the 2-ΔΔCt
method.
Transfections and treatments
Stable PAK4 knockdown cell lines (MiaPaCa-shPAK4 and T3M4-shPAK4) were
generated previously [22]. To dissect the role of the STAT3 signaling pathway, PAK4-
expressing PC (MiaPaCa- and T3M4-NTScr) cells were cultured in 6-well plates and
transfected with 30 nM of human STAT3 speciﬁc siRNAs, while in another ap-
proach PAK4-silenced PC cells (MiaPaCa- and T3M4-shPAK4) were transduced with
a lentivirus expressing a constitutively active mutant form of STAT3
(EF.STAT3C.Ubc.GFP) and respective control vector (FUGW). For deciphering the role
of PAK4 in chemoresistance, cells were treated with increasing concentration of
gemcitabine (0–10 μM) for 72 h and cell viability was calculated using WST-1 assay
kit (Roche, Indianapolis, IN) as described earlier [28].
Immunoblot analysis
Immunoblotting was performed as described earlier [29] using speciﬁc anti-
bodies against various proteins. β-actin, α-tubulin and Lamin A were used as loading
controls for total, cytoplasmic and nuclear proteins, respectively. All the primary an-
tibodies were used at 1:1000 dilution whereas all the secondary antibodies were
used at 1:2500 dilution. β-actin was used at 1:20,000 dilution. The signal was de-
tected using ECL plus Western Blotting substrate (Thermo Scientiﬁc, Logan, UT) and
LAS-3000 image analyzer (Fuji Photo Film Co., Tokyo, Japan).
Nuclear and cytoplasmic fractionation
The preparation of cytoplasmic and nuclear extracts was performed using the
nuclear extract kit (Active Motif, Carlsbad, CA) as described previously [22,30].
STAT3 transcriptional activity assay
The transcriptional activity of STAT3 was measured by Cignal STAT3 Reporter
(Luc) kit (SA Bioscience, Valencia, CA) according tomanufacturer’s instructions. Brieﬂy,
PC cells were grown in 6-well plate and transiently transfected with 1.0 μg of STAT3
reporter along with negative control. STAT3 reporter is a mixture of inducible STAT3-
responsive ﬁreﬂy luciferase construct and constitutively expressing Renilla luciferase
construct (40:1). Negative control is a mixture of non-inducible ﬁreﬂy luciferase con-
struct and constitutively expressing Renilla luciferase construct (40:1). After 48 h
of transfection, cells were harvested in passive lysis buffer and luciferase activity
was measured using the Dual Luciferase Assay System (Promega, Madison, WI).
Clonogenicity and sphere formation assay
The clonogenicity and sphere formation assayswere performed as described pre-
viously [31,32]. Brieﬂy, for sphere formation assay, cells (1 × 103/well) were seeded
in the 6-well ultralow attachment plate in 2 mL of stem cell culture medium and on
every alternate day the mediumwas supplemented with 2% B27, 20 ng/mL EGF and
20 ng/mL FGF-b. After 10 days, the pancreatospheres larger than 50 μmwere counted
and photographed using phase contrast microscope as described previously [32].
Statistical analysis
All the experiments were performed at least three times independently, and all
data are expressed as “mean ± SD”. Wherever appropriate, the data were also sub-
jected to unpaired two tailed Student’s t-test. p < 0.05 was considered statistically
signiﬁcant.
Results
PAK4 is highly expressed in pancreatic cancer stem cells
To investigate the role of PAK4 in stemness of PC cells, we iso-
lated cancer stem cells (CSCs) from two PAK4 expressing highly
aggressive PC cell lines (MiaPaCa and T3M4) by ﬂow-cytometry using
a set of previously characterized phenotypic biomarkers, viz. CD24,
CD44 and EpCAM [8]. Sub-set of PC cells with high expression of
CD24, CD44 and EpCAM was designated as CSCs (CD24+/CD44+/
EpCAM+) while cells with no or negligible expressionwere designated
as non-CSCs (CD24−/CD44−/EpCAM−). Apparently, ~3.3% (MiaPaCa)
and ~6.0% (T3M4) cells were identiﬁed as CSC population while the
fraction of non-CSCs was ~3.0 and ~11.1% inMiaPaCa and T3M4 cells,
respectively (Fig. 1A). Furthermore, we also examined the expression
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of PAK4 in CSCs (CD24+/CD44+/EpCAM+) and non-CSCs (CD24−/
CD44−/EpCAM−) by immunoblot analysis. We observed that the
expression level of PAK4 is remarkably higher in CSCs (CD24+/
CD44+/EpCAM+) as compared to non-CSCs (CD24−/CD44−/EpCAM−)
in both the cell lines (MiaPaCa and T3M4) (Fig. 1B). The densitom-
etry analyses show that the expression of PAK4 is 8.0- and 7.7-
fold higher in CSCs of MiaPaCa and T3M4 cells, respectively (Fig. 1C).
Together, these ﬁndings suggest that PAK4 is highly expressed in
pancreatic cancer stem cells.
Silencing of PAK4 reduces the expression of stemness-associated
markers in PC cells
Having observed the elevated expression of PAK4 in CSCs, we
sought to investigate its signiﬁcance in PC stemness. For this, we
used PAK4-silenced (-shPAK4) stable sublines of MiaPaCa and T3M4
cells (Fig. S1) and examined the expression of various stemness-
associated markers (CD24, CD44 and EpCAM) by ﬂow-cytometry.
We observed that the individual geometric mean ﬂuorescence in-
tensity (MFI) of CD24, CD44 and EpCAMwas considerably decreased
in PAK4-silenced PC cells (Fig. 2A). The relative MFI of CD24, CD44
and EpCAM is reduced by 20.0%, 26.8% and 38.5%, respectively, in
MiaPaCa-shPAK4 cells, while it was decreased by 40.0%, 28.3% and
46.3%, respectively, in PAK4-silenced T3M4 cells (Fig. 2A). Since pan-
creatic CSCs are also known to be enriched with aldehyde
dehydrogenase (ALDH1) [33], we explored whether PAK4 silenc-
ing has any effect on ALDH1 level. Data from ﬂow-cytometry analysis
demonstrate that the number of ALDH1 positive cells is remark-
ably decreased ~2.5 fold (MiaPaCa) and ~1.7 fold (T3M4) upon
silencing of PAK4 (Fig. S2). Furthermore, we conﬁrmed all these ﬁnd-
ings by performing quantitative RT-PCR assays. Similar to our ﬂow
cytometry data, we found that the expression level of CD24, CD44,
EpCAM and ALDH1 was signiﬁcantly decreased in low PAK4 ex-
pressing (MiaPaCa- and T3M4-shPAK4) cells in comparison to their
control cells (MiaPaCa- and T3M4-NTScr) at mRNA level (Fig. 2B).
In addition, we also examined the effect of PAK4 silencing on the
expression of stemness-associated transcription factors (KLF4, Sox2,
Nanog and Oct4) at mRNA level. Data demonstrate a drastic de-
crease in the level of KLF4, Sox2, Nanog and Oct4 in PAK4 silenced
MiaPaCa and T3M4 cells (Fig. 2B). PAK4-silencing induced
downregulation of KLF4, Sox2, Nanog and Oct4 was further vali-
dated at protein level by immunoblot assay (Fig. 2C).
Silencing of PAK4 suppresses sphere formation ability and chemo-
resistance in PC cells
Unlimited self-renewal potential to maintain their undifferen-
tiated state is a hallmark of CSCs [6]. Therefore, we next sought to
investigate the role of PAK4 in the self-renewal ability of pancre-
atic CSCs by sphere formation assay. For this, PAK4-silenced sublines
(-shPAK4) of MiaPaCa and T3M4 cells were seeded at low density
(1 × 103/well) along with their high PAK4-expressing (MiaPaCa- and
T3M4-NTScr) counterparts in low attachment plate. The cells were
allowed to grow in stem cell culture medium for 10 days and the
number of spheres formed was counted. We observed lesser sphere
forming ability in PAK4-silenced PC cells as compared to PAK4 ex-
pressing cells (Fig. 3A). The data demonstrate 4.4-fold and 3.8-
fold greater sphere formation in MiaPaCa-NTScr and T3M4-NTScr
cells, respectively, as compared to MiaPaCa-shPAK4 and T3M4-
shPAK4 cells (Fig. 3A).
Resistance to chemo-therapeutic agents is another key charac-
teristic of CSCs [6,7]. To examine the signiﬁcance of PAK4 in
chemoresistance, PAK4-expressing and -silenced cells were treated
with increasing doses of gemcitabine and the effect on growth was
Fig. 1. PAK4 expression analysis in pancreatic cancer stem cells (CD44+/CD24+/EpCAM+) and non-CSCs (CD44−/CD24−/EpCAM−). (A) Pancreatic cancer stem cells (CSCs) were
isolated from PAK4 expressing MiaPaCa and T3M4 PC parent cells on the basis of triple positive and negative CD24, CD44, and EpCAM surface markers using ﬂow-
cytometry. (B) PAK4 expression was analyzed in pancreatic CSCs (CD44+/CD24+/EpCAM+) and non-CSCs (CD44−/CD24−/EpCAM−) by immunoblot assay using PAK4 speciﬁc
antibody. β-actin was used as an internal control. (C) Relative expression of PAK4 in CSCs and non-CSCs isolated from MiaPaCa and T3M4 cells estimated by densitometry.
Error bars represent the mean ± SD; n = 3; *p < 0.05.
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examined by short-term (WST1 assay) and long-term (colony-
formation) growth assays. Our data showed that PAK4-silenced cells
(MiaPaCa- and T3M4-shPAK4) were more sensitive to gemcitabine-
cytotoxicity as compared to respective control cells in both short-
term (Fig. 3B) and long-term (Fig. 3C) growth assays. Data show
signiﬁcantly (p ≤ 0.01) lower IC50 values of gemcitabine ~2.08 μM
in MiaPaCa-shPAK4 and 1.54 μM in T3M4-shPAK4 cells as com-
pared toMiaPaCa-NTScr (~5.53 μM) and T3M4-NTScr (~3.44 μM) cells
(Fig. 3B). Importantly, the chemosensitizing effect of PAK4 silenc-
ing is more prominent in long-term assay as evidenced by very few
or no visible colonies in PAK4 silenced cells at 1.0 and 2.5 μM
gemcitabine doses. Taken together, our ﬁndings suggest that PAK4
enhances stem cell-associated phenotypes in PC cells.
PAK4 enhances stemness potential via activation of STAT3 signaling
in PC cells
Signal transducer and activator of transcription 3 (STAT3) remains
constitutively active in various cancer types including PC and plays
pivotal role in proliferation and self-renewal of CSCs [34,35]. There-
fore, we investigated the involvement of STAT3 in PAK4-induced
stemness in PC cells. For this, we ﬁrst examined the effect of PAK4
silencing on the transcriptional activity of STAT3 by luciferase-
based promoter reporter assay. Data show that the transcriptional
activity of STAT3 responsive promoter is decreased by ~3.1 fold
(MiaPaCa) and ~2.2 fold (T3M4) upon silencing of PAK4 (Fig. 4A).
These ﬁndings were further conﬁrmed by analyzing the cellular
Fig. 2. PAK4 induces expression of stemness-associated markers in PC cells. (A) PAK4-expressing and silenced cells were incubated with ﬂuorochrome-conjugated anti-
CD24, -CD44 and -EpCAM antibodies for 15min on ice, followed by washing with PBS and subjected to FACS analysis. The data are presented as geometric mean of ﬂuorescence
intensity (MFI). The expression of other stemness associated markers was examined (B) at mRNA level by quantitative RT-PCR (mean ± SD; n = 3; *p < 0.05) and (C) protein
level by immunoblot assay. β-actin was used as an internal control.
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localization and activation status of STAT3 in low and high PAK4-
expressing PC cells by immunoblot assay. An enhanced nuclear level
with concomitant decreased cytoplasmic level of STAT3 is ob-
served in high PAK4 expressing (MiaPaCa-NTScr and T3M4-NTScr)
cells as compared to low PAK4 expressing (MiaPaCa-shPAK4 and
T3M4-shPAK4) cells (Fig. 4B). In addition, signiﬁcantly decreased
phosphorylation of STAT3 in PAK4-silencedMiaPaCa as well as T3M4
cells is observed (Fig. 4C).
Fig. 3. PAK4 facilitates sphere formation and drug resistance in PC cells. PAK4 expressing or silenced MiaPaCa and T3M4 cells (1 × 103) were seeded in ultra-low attach-
ment plate and allowed to grow for 10 days in stem cell culture medium. (A) Images were taken under light microscope at 200× magniﬁcation and the number of spheres
(size > 50 μm) was counted. Error bars represent the mean ± SD; n = 3; *p < 0.05. (B) PAK4 expressing or silenced PC cells were treated with indicated doses of gemcitabine
(0–10 μM) for 72 h. Cell viability was analyzed by WST-1 assay. OD value of untreated cells was taken as 100% viable. Data represent the mean ± SD; n = 3; *p < 0.01.
(C) Representative images of colonies formed by PAK4-expressing and -silenced cells treated with various concentrations of gemcitabine (0, 0.5, 1.0 and 2.5 μM) for 24 h
and further allowed to form colonies for 2 weeks.
Fig. 4. PAK4 induces transcriptional activity of STAT3 in human PC cells by promoting its nuclear translocation. The cells were co-transfected with Cignal STAT3 reporter
(mixture of STAT3-responsive ﬁreﬂy luciferase reporter and Renilla luciferase plasmids) and negative control plasmids. (A) After 48 h, cells were harvested in passive lysis
buffer and luciferase activity was assessed using a dual-luciferase assay system. Data are presented as normalized relative luciferase activity (mean ± SD; n = 3, *p < 0.05).
Total, nuclear and cytoplasmic extracts were prepared and (B) cellular localization of STAT3 and (C) expression level of pSTAT3 or total were analyzed by immunoblot anal-
ysis. Lamin A (for nuclear fraction), α-tubulin (for cytoplasmic fraction) and β-actin (for total fraction) were used as loading controls.
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To validate whether STAT3 is involved in PAK4-induced stemness
in PC cells, low PAK4 expressing (MiaPaCa-shPAK4 and T3M4-
shPAK4) cells were transiently transfected with constitutively active
mutant of STAT3 (STAT3C) and the effect on transcriptional activ-
ity of STAT3, stemness-associated markers and sphere-forming
potential was examined. Our data demonstrate that transcrip-
tional activity (Fig. 5A) is restored in PAK4-silenced MiaPaCa and
T3M4 cells transfected with active mutant of STAT3, which is as-
sociated with increased nuclear and decreased cytoplasmic level of
STAT3 in these cells (Fig. 5B). Notably, we observed regain of
stemness-associated markers (Oct4, Sox2 and Nanog) in PAK4-
silenced PC cells upon transfection of active mutant of STAT3
(Fig. 6A). Moreover, sphere-forming ability of PAK4-silenced cells
is also restored after forced activation of STAT3 in these cells (Fig. 6B).
These ﬁndings were further conﬁrmed by reverse approach where
STAT3 expression was silenced in MiaPaCa-NTScr and T3M4-
NTScr cells (Fig. S3). Taken together, our ﬁndings suggest that PAK4-
induces stemness potential in PC cells through activation of STAT3.
Discussion
In spite of advances in surgery and chemotherapy, the mortal-
ity rate of PC remains very high due to lack of effective therapy and
late diagnosis. Chemoresistance imposes one of the major clinical
problems in PC treatment. Recent studies have shown that CSCs,
characterized by high expression of ESA, CD24 and CD44 surface
proteins in PC [8], are the main entity responsible for therapy re-
sistance and tumor recurrence [5,9,11–13]. Therefore, therapeutic
targeting of CSCs along with bulk epithelial tumor cells would have
profound clinical implications for better management of this disease.
In this study, we demonstrated, for the ﬁrst time, that PAK4 ex-
pression is associated with increased stemness characteristics like
high expression of stemness-associated markers, sphere-forming
ability as well as chemoresistance.
Li et al. used CD24, CD44 and ESA markers alone or in combi-
nation for isolating the CSC population from pancreatic tumors [8].
Their study revealed that pancreatic tumor cells that were posi-
tive for all three (CD24, CD44 and ESA) surface molecules exhibited
greater self-renewal capacity and were highly tumorigenic in nature
as compared to pancreatic tumor cells that were positive for single
or double markers [8]. Ohara et al. investigated the clinical signif-
icance of CD44+/CD24+/EpCAM+ cells in pancreatic adenocarcinoma.
Their study suggested that the presence of CD44+/CD24+/EpCAM+
cells correlates with poor differentiation [36]. Moreover, CD44+/
CD24+ cells are associated with poor prognosis of pancreatic cancer
patients [36]. Additionally, high rate of chemoresistance in PC is sug-
gested to be attributed to CD44, CD24, and EpCAM positive stem
cells [37]. The present study demonstrated that the level of PAK4
was considerably high in triple positive (CD24+/CD44+/EpCAM+) pan-
creatic CSCs as compared to non-CSCs (CD24−/CD44−/EpCAM−).
Moreover, silencing of PAK4 in high PAK4 expressing (MiaPaCa and
T3M4) PC cells led to reduction in expression of CD24, CD44 and
EpCAM. These complementary sets of data provide a direct support
for the association of high PAK4 levels with pancreatic CSCs.
In addition to the CD44, CD24 and EpCAM, we also observed de-
creased expression of other stemness-associated markers including
ALDH1, KLF4, Oct4, Sox2 and Nanog in PAK4-silenced PC cells. Enor-
mous studies are available to support the role of ALDH1, KLF4, Oct4,
Sox2 and Nanog in stemness potential of different cancer types in-
cluding PC [38–42]. Wei et al. reported that KLF4 is up-regulated
in PC, and its expression inversely correlates with the survival of
PC patients [43]. Overexpression of Oct4 and Nanog in PDAC is as-
sociated with early state carcinogenesis [44] and worst prognosis
[45]. These studies indicate that KLF4, Oct4, and Nanog may con-
tribute to PC pathobiology via enhancing the stemness potential of
pancreatic tumor cells. Sox2 expression has been associated with
increased levels of the stem cell markers, viz. ALDH1, EpCAM and
CD44, in pancreatic tumor and CD44/EpCAM positive CSCs iso-
lated from pancreatic tumor specimens have enhanced expression
of Sox2 [46]. Rasheed et al. established the role of ALDH1 in the
maintenance of stem cells potential of PC [33]. Together, these
Fig. 5. Forced expression of STAT3 active mutant restores transcriptional activity and
localization of STAT3 in PAK4-silenced PC cells. In this approach, PAK4 silenced cells
were transfected with constitutively active STAT3 mutant (EF.STAT3C.Ubc.GFP) or
empty vector (FUGW) and (A) after 48 h transfection, cells were again transfected
with STAT3 luciferase promoter-reporter plasmid and transcriptional activity of STAT3
was examined. Data are presented as normalized relative luciferase activity
(mean ± SD; n = 3, *p < 0.05). (B) Nuclear and cytoplasmic fractions were prepared
after 24 h of transfection and expression level of STAT3was examined by immunoblot
analysis. Lamin A (for nuclear fraction), α-tubulin (for cytoplasmic fraction) and β-actin
(for total fraction) were used as loading controls.
Fig. 6. STAT3-mediates PAK4-induced stemness in PC cells. (A) The expression of
stem cell markers was analyzed by immunoblot analysis. β-actin was used as an in-
ternal control. (B) After transfection, cells were cultured in ultra-low attachment plate
to analyze the effect of STAT3 on sphere-forming potential of these cells by sphere
forming capacity. Sphere >50 μm in diameter was counted at 200× magniﬁcation
(mean ± SD; n = 3, *p < 0.05).
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ﬁndings add further support for the association of PAK4 with pan-
creatic CSCs.
Enhanced sphere-forming potential and resistance to therapy
are the main characteristics of CSCs [6,9]. It is widely accepted that
the resistance to chemotherapeutic agents is largely attributed to
self-renewing subpopulations of CSCs present in the bulk tumor.
Earlier studies have shown that pancreatic CSCs confer increased
resistance towards 5-ﬂuorouracil (5-FU) and gemcitabine [47,48].
We demonstrated that PAK4-silencing not only reduced the ex-
pression of stemness markers, but also decreased the sphere
formation ability of PC cells. Moreover, PAK4 silencing caused sen-
sitization of PC cells against gemcitabine-induced toxicity. Enhanced
chemoresistance ability of CSCs is majorly due to their enhanced
survival mechanisms [49] as compared to the other cells of the
tumor bulk. In this regard, our earlier ﬁndings supporting a direct
role of PAK4 with increased survival of PC cells are highly relevant
[22]. We observed that PAK4-overexpressing PC cells exhibited en-
hanced expression of anti-apoptotic proteins (Bcl-2 and Bcl-xL) [22],
which are shown to confer apoptosis-resistance to CSCs [50,51].
PAK4 has been shown to promote chemoresistance in other cancer
types as well [52,53] suggesting its universal association with CSC
phenotypes.
Using various experimental approaches, we demonstrated a role
of STAT3, an oncogenic transcription factor, in PAK4-induced ex-
pression of stem cell-associated markers and sphere-forming
potential of pancreatic tumor cells. In the aspect of pancreatic car-
cinogenesis, it has been suggested that STAT3 is frequently
overexpressed in PC [35,54] and plays a vital role in PC pathogen-
esis by regulating genes involved in proliferation, survival, and
metastasis of pancreatic tumor cells [55–57]. In addition, a role of
STAT3 in the maintenance of stemness behavior in various tumor
types, including PC, has also been well documented [34,58–60]. Re-
cently, Guha et al. revealed the important role of STAT3 in nicotine-
induced apoptosis resistance and CSC characteristics in breast cancer
cells [61]. Furthermore, the important role of STAT3/Sox2 axis in
maintaining stem cell phenotypes in PC cells has also been docu-
mented [62]. Notably, apart from maintaining the stemness
phenotypes in tumor cells, STAT3 activation is also suggested to
convert non-CSCs to CSCs [63]. The precise molecular mecha-
nism(s) responsible for the activation of STAT3 in PC is not well
understood. In this regard, our ﬁndings suggesting PAK4 as an up-
stream activator of STAT3 are highly innovative. However, the
signaling axis/molecules involved in PAK4-mediated STAT3 activa-
tion need to be explored in future studies.
In conclusion, the present study establishes a direct associa-
tion of PAK4 with pancreatic cancer stemness, an effect that is
mediated through STAT3 activation. Thus, targeting of PAK4 could
be of great signiﬁcance for not only managing the bulk tumor cells,
but CSCs as well. Therefore, development of novel approaches for
inhibiting PAK4 activity in PC should be the next logical step that
could lead to an effective cure for this devastating malignancy.
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